Sign In
Buy RVPH
$0.695
+0.0350 (+5.30%)
At Close: Jun 23, 2026
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
08:00am, Thursday, 25'th Jan 2024
CUPERTINO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
07:32am, Tuesday, 23'rd Jan 2024
Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some
Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
08:00am, Wednesday, 10'th Jan 2024
CUPERTINO, CA / ACCESSWIRE / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to a
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones
08:00am, Thursday, 04'th Jan 2024
– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE) trial, and positive drug-drug interaction data su
Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
04:05pm, Thursday, 30'th Nov 2023
CUPERTINO, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva Pharmaceuticals: Positive Results In Phase 3 But The Stock Is Back Where It Started
03:11am, Thursday, 02'nd Nov 2023
Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg dose beat placebo on the primary endpoint. The 15 mg dose of brilarox
Reviva Pharma's schizophrenia drug succeeds in late-stage study
07:41am, Monday, 30'th Oct 2023
Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study.
Reviva Pharmaceuticals: A Binary Event Approaches With Results From RECOVER
02:48am, Wednesday, 27'th Sep 2023
Reviva Pharmaceuticals is running a phase 3 study of brilaroxazine in schizophrenia called RECOVER, with results expected in October 2023. A previous phase 2 study showed that brilaroxazine had signif
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
06:00am, Thursday, 07'th Sep 2023
CUPERTINO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August
08:00am, Monday, 31'st Jul 2023
CUPERTINO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therap
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June
06:00am, Thursday, 15'th Jun 2023
CUPERTINO, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therap
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023
06:30am, Thursday, 18'th May 2023
CUPERTINO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapi
Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
06:30am, Friday, 12'th May 2023
CUPERTINO, Calif., May 12, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapi
Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023
06:00am, Thursday, 04'th May 2023
CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapi
CUPERTINO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing thera
